16 Analysts Have This to Say About Gilead Sciences
Within the last quarter, Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Piper Sandler Maintains Overweight on Gilead Sciences, Raises Price Target to $111
Piper Sandler analyst Do Kim maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $104 to $111.
Wells Fargo Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $90
Wells Fargo analyst Mohit Bansal maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and raises the price target from $75 to $90.
European Medicines Agency Validates Marketing Authorization Application For Trodelvy For Pre-Treated HR+/HER2- Metastatic Breast Cancer
– Application Based on Statistically Significant and Clinically Meaningful Overall Survival and Progression-Free Survival Results from the Phase 3 TROPiCS-02 Study –
– Supplemental Biologics License
RBC Capital Downgrades Gilead Sciences to Sector Perform, Announces $87 Price Target
RBC Capital analyst Brian Abrahams downgrades Gilead Sciences (NASDAQ:GILD) from Outperform to Sector Perform and announces $87 price target.
New Oral COVID-19 Antiviral Might Be Better Than Pfizer’s Paxlovid With Faster Recovery, Fewer Side Effects, Data Shows
A study in China shows that a remdesivir analog, dubbed VV116, is as effective as Pfizer Inc's (NYSE: PFE) oral COVID-19 pill.
Gilead Sciences Acquires Jounce Therapeutics Cancer Immunotherapy Program
Gilead Sciences Inc (NASDAQ:GILD) and Jounce Therapeutics Inc (NASDAQ:JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to…
Tesla, Apple, Lightjump, Southwest, Gilead: Why These 5 Stocks Are Drawing Investors’ Attention Today
U.S. markets opened lower on Tuesday in a truncated week after rising bond yields dragged major growth stocks and indices.
Biogen’s 2nd Alzheimer’s Antibody, BeiGene’s Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022.